Tarceva erlotinib: Phase IIIb data

Additional data from the Phase IIIb SATURN trial in 889 patients with advanced, recurrent or metastatic NSCLC showed that first-line therapy with Tarceva erlotinib produced a 41% improvement in PFS vs...